|
MechanismCMV DNA terminase inhibitors |
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.Canada |
First Approval Date01 Nov 2017 |
/ CompletedNot Applicable 一项评价泊沙康唑(MK-5592)静脉制剂在中国侵袭性真菌感染高危受试者中的药代动力学和安全性研究
[Translation] A study evaluating the pharmacokinetics and safety of intravenous posaconazole (MK-5592) in Chinese subjects at high risk for invasive fungal infections
本研究旨在评估POS静脉输注液(300 mg,第1天Q12hr给药,随后QD给药)在中国侵袭性真菌感染高危受试者中的药代动力学特征,以及安全性和耐受性,以支持其在中国的注册。
[Translation] This study aims to evaluate the pharmacokinetic characteristics, safety, and tolerability of POS intravenous infusion (300 mg, administered Q12hr on day 1 and then QD) in Chinese subjects at high risk of invasive fungal infections to support its registration in China.
100 Clinical Results associated with Organon Heist BV
0 Patents (Medical) associated with Organon Heist BV
100 Deals associated with Organon Heist BV
100 Translational Medicine associated with Organon Heist BV